Loss of Microbiota-Mediated Colonization Resistance to Clostridium difficile Infection with Oral Vancomycin Compared with Metronidazole

Journal of Infectious Diseases

Volumn 212, Issue 10, 2015, Pages 1656-1665

  Lewis, Brittany B ^a   Buffie, Charlie G ^a   Carter, Rebecca A ^a   Leiner, Ingrid ^a   Toussaint, Nora C ^a,b,c   Miller, Liza C ^a   Gobourne, Asia ^a   Ling, Lilan ^a   Pamer, Eric G ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b The Computational Biology Center   (United States)

^c NEW YORK GENOME CENTER   (United States)

Author keywords

Clostridium difficile; Colonization resistance; Metronidazole; Microbiota; Vancomycin

Indexed keywords

METRONIDAZOLE; RNA 16S; VANCOMYCIN; ANTIINFECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DNA EXTRACTION; ENTEROCOCCAL INFECTION; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTION; FEMALE; GENE AMPLIFICATION; KLEBSIELLA PNEUMONIAE; KLEBSIELLA PNEUMONIAE INFECTION; MICROFLORA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEQUENCE ANALYSIS; VANCOMYCIN RESISTANT ENTEROCOCCUS; ANIMAL; BACTERIAL INFECTION; C57BL MOUSE; DISEASE MODEL; DISEASE RESISTANCE; DRUG EFFECTS; IMMUNOLOGY; ISOLATION AND PURIFICATION; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE;

ANIMALS; ANTI-INFECTIVE AGENTS; BACTERIAL INFECTIONS; CLOSTRIDIUM DIFFICILE; DISEASE MODELS, ANIMAL; DISEASE RESISTANCE; ESCHERICHIA COLI; FEMALE; KLEBSIELLA PNEUMONIAE; METRONIDAZOLE; MICE, INBRED C57BL; VANCOMYCIN; VANCOMYCIN-RESISTANT ENTEROCOCCI;

EID: 84983048071     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiv256     Document Type: Article

References (32)

1. Bartlett JG. Historical perspectives on studies of Clostridium difficile and C. difficile infection. Clin Infect Dis 2008; 46(suppl 1):S4-11.
2. McDonald LC, Killgore GE, Thompson A, et al. An epidemic, toxin genevariant strain of Clostridium difficile. N Engl J Med 2005; 353:2433-41.
3. He M, Miyajima F, Roberts P, et al. Emergence and global spread of epidemic healthcare-associated Clostridium difficile. Nat Genet 2013; 45: 109-13.
4. Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. http://www.cdc.gov/drugresistance/threatreport- 2013/. Accessed 16 January 2015.
5. Pépin J, Valiquette L, Alary M-E, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. Can Med Assoc J 2004; 171:466-72.
6. Feuerstadt P, Das R, Brandt LJ. The evolution of urban C. difficile infection (CDI): CDI in 2009-2011 is less severe and has better outcomes than CDI in 2006-2008. Am J Gastroenterol 2014; 109:1265-76.
7. Bauer MP, Notermans DW, van Benthem BH, et al. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011; 377:63-73.
8. Slimings C, Riley TV. Antibiotics and hospital-acquired Clostridium difficile infection: update of systematic review and meta-analysis. J Antimicrob Chemother 2014; 69:881-91.
9. Garey KW, Sethi S, Yadav Y, DuPont HL. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008; 70:298-304.
10. Perras C, Tsakonas E, Ndegwa S, Conly J, Valiquette L, Farrah K. Vancomycin or metronidazole for treatment of Clostridium difficile infection: clinical and economic analyses. http://www.ncbi.nlm.nih.gov/ pubmedhealth/PMH0063523/. Accessed 15 December 2014.
11. Drekonja DM, Butler M, MacDonald R, et al. Comparative effectiveness of Clostridium difficile treatments: a systematic review. Ann Intern Med 2011; 155:839-47.
12. Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficileassociated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45:302-7.
13. Johnson S, Louie TJ, Gerding DN, et al. Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials. Clin Infect Dis 2014; 59:345-54.
14. Rodriguez S, Hernandez MB, Tarchini G, et al. Risk of Clostridium difficile infection in hospitalized patients receiving metronidazole for a non-C difficile infection. Clin Gastroenterol Hepatol 2014; 12:1856-61.
15. Saade E, Deshpande A, Kundrapu S, et al. Appropriateness of empiric therapy in patients with suspected Clostridium difficile infection. Curr Med Res Opin 2013; 29:985-8.
16. Abujamel T, Cadnum JL, Jury LA, et al. Defining the vulnerable period for re-establishment of Clostridium difficile colonization after treatment of C. difficile infection with oral vancomycin or metronidazole. PLoS One 2013; 8:e76269.
17. Buffie CG, Jarchum I, Equinda M, et al. Profound alterations of intestinal microbiota following a single dose of clindamycin results in sustained susceptibility to Clostridium difficile-induced colitis. Infect Immun 2012; 80:62-73.
18. Ubeda C, Taur Y, Jenq RR, et al. Vancomycin-resistant Enterococcus domination of intestinal microbiota is enabled by antibiotic treatment in mice and precedes bloodstream invasion in humans. J Clin Invest 2010; 120:4332-41.
19. Buffie CG, Bucci V, Stein RR, et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 2015; 517:205-8.
20. Schloss PD, Westcott SL, Ryabin T, et al. Introducing mothur: opensource, platform-independent, community-supported software for describing and comparing microbial communities. Appl Environ Microbiol 2009; 75:7537-41.
21. DeSantis TZ, Hugenholtz P, Larsen N, et al. Greengenes, a chimerachecked 16S rRNA gene database and workbench compatible with ARB. Appl Environ Microbiol 2006; 72:5069-72.
22. Sheneman L, Evans J, Foster JA. Clearcut: a fast implementation of relaxed neighbor joining. Bioinformatics 2006; 22:2823-4.
23. Lozupone C, Knight R. UniFrac: a new phylogenetic method for comparing microbial communities. Appl Environ Microbiol 2005; 71: 8228-35.
24. Anderson MJ. A new method for non-parametric multivariate analysis of variance. Austral Ecology 2001; 26:32-46.
25. Chen X, Katchar K, Goldsmith JD, et al. A mouse model of Clostridium difficile-associated disease. Gastroenterology 2008; 135:1984-92.
26. Owens RC. Clostridium difficile-associated disease: an emerging threat to patient safety: insights from the society of infectious diseases pharmacists. Pharmacotherapy 2006; 26:299-311.
27. Aslam S, Hamill RJ, Musher DM. Treatment of Clostridium difficileassociated disease: old therapies and new strategies. Lancet Infect Dis 2005; 5:549-57.
28. Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011; 364: 422-31.
29. Eyre DW, Babakhani F, Griffiths D, et al. Whole-genome sequencing demonstrates that fidaxomicin is superior to vancomycin for preventing reinfection and relapse of infection with Clostridium difficile. J Infect Dis 2014; 209:1446-51.
30. Ubeda C, Lipuma L, Gobourne A, et al. Familial transmission rather than defective innate immunity shapes the distinct intestinal microbiota of TLR-deficient mice. J Exp Med 2012; 209:1445-56.
31. Warren CA, van Opstal EJ, Riggins MS, et al. Vancomycin treatment's association with delayed intestinal injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Antimicrob Agents Chemother 2013; 57:689-96.
32. Bassis CM, Theriot CM, Young VB. Alteration of the murine gastrointestinal microbiota by tigecycline leads to increased susceptibility to Clostridium difficile infection. Antimicrob Agens Chemother 2014; 58:2767-74.